Applied Molecular Transport: Presentation of the AMT Research & Development Day
This presentation and any accompanying oral presentation contain forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, and management’s objectives for future operations, as well than
as statements regarding industry trends, are forward-looking statements. In some cases, you may identify forward-looking statements by words such as “estimate”, “intend”, “may”, “may be”, “plan”, “,,,”, “or the negative of these terms or other similar expressions.
We have based these forward-looking statements in large part on our current expectations and projections regarding future events and trends that we believe could affect our financial condition, results of operations, business strategy and financial needs. These statements include, without limitation, the potential and expectations regarding the potential, potential benefits and expectations regarding the technology platform of AMT, AMT-101 and AMT-126, statements regarding the market potential AMT’s product candidates, statements regarding AMT’s Phase 2 clinical trials for AMT-101 and AMT’s Phase 1 clinical trials for AMT-126, including the timing of these trials, recruitment of these trials, the milestones and expectations for data readings from these clinical trials, and AMT’s ability to leverage its technology to expand its pipeline, including our ability to expand our technology platform by expanding therapies to treat respiratory diseases. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the launch timing, progress and potential results of our preclinical studies, clinical trials and research programs. ; our ability to use and extend our technology platform to create a pipeline of product candidates; uncertainty about the development of biological therapies; our ability to advance product candidates and complete them in clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients suffering from the diseases we target and the number of patients who may participate in our clinical trials; the marketing of our product candidates, if approved; our ability and potential to successfully manufacture and supply our product candidates for clinical trials and for commercial purposes, if approved; future strategic agreements and / or collaborations and the potential benefits of such agreements; our estimates of expenses, future revenues, capital requirements and additional financing requirements and our ability to raise additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure needs; our ability to retain the ongoing service of our key personnel and to identify, hire and retain additional qualified personnel; implementing our strategic plans for our business and product candidates; the extent of protection we are able to establish and maintain for intellectual property rights, including our technology platform, product candidates and research programs; our ability to contract with third party suppliers and manufacturers and their ability to function properly; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors and our industry, including competing product candidates and therapies; the negative impacts of the COVID-19 pandemic on our operations; and other risks. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors. Actual results may differ materially from those of forward-looking statements due to a number of factors, including those described in documents filed by the Company with the Securities and Exchange Commission. You should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results, activity levels, performance or achievements. Except as required by law, we do not undertake to publicly update any forward-looking statements for any reason after the date of this presentation.
This presentation also contains estimates and other statistical data made by independent parties and by us regarding market size and growth and other data about our industry. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
This presentation concerns product candidates under clinical investigation and whose marketing has not yet been approved by the US Food and Drug Administration (FDA). These product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.
This is an excerpt from the original content. To continue reading it, go to the original document here.